This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will Tavalisse Continue to Drive Rigel Pharmaceuticals' Growth in 2026?
by Sundeep Ganoria
RIGL's 2025 sales jump 60% to $232M, led by Tavalisse. With 2026 product sales seen at $255-$265M, can its momentum withstand rising competition?
SNYPositive Net Change LLYPositive Net Change RIGLPositive Net Change
biotechs medical pharmaceuticals
Stock Market News for Feb 18, 2026
by Zacks Equity Research
U.S. stock markets closed higher on Tuesday. Stock prices were muted yesterday as major indexes were mostly sidetracked.
CNHPositive Net Change KRYSNegative Net Change
biotechs industrial-products
New Strong Sell Stocks for February 18th
by Zacks Equity Research
COIN, NBIX and UPST have been added to the Zacks Rank #5 (Strong Sell) List on February 18th, 2026.
NBIXPositive Net Change UPSTNegative Net Change COINPositive Net Change
biotechs
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?
by Kanishka Das
CRMD stock sinks 27% in 3 months as its bearish 2026 outlook for DefenCath clouds near-term growth, raising investor concern.
PFENegative Net Change AMPHNegative Net Change CRMDNegative Net Change
biotechs
Arcutis Biotherapeutics to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
ARQT heads into Q4 earnings with Zoryve sales momentum, while investors eye pipeline updates on Feb. 25.
AXSMPositive Net Change CSTLNegative Net Change IMVTNegative Net Change ARQTPositive Net Change
biotechs
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
by Ekta Bagri
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
BMYPositive Net Change MRKPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA talks.
AXSMPositive Net Change CSTLNegative Net Change IMVTNegative Net Change RXRXPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
What to Expect From These Drug/Biotech Players This Earnings Season?
by Ekta Bagri
Let's take a closer look at what awaits Bausch Health, Amicus Therapeutics, BioMarin Pharmaceutical, Insmed and Madrigal Pharmaceuticals as they prepare to report quarterly results this week.
BMRNPositive Net Change FOLDPositive Net Change INSMPositive Net Change MDGLNegative Net Change BHCNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.
NVONegative Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
by Zacks Equity Research
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
RHHBYNegative Net Change BMYPositive Net Change NVONegative Net Change PRTANegative Net Change
biotechs